
Pharmaceutical firm Novo Nordisk will not focus its attention exclusively on adults and adolescents when the pivotal testing phase of hemophilia drug Mim8 begins later this year.
According to database Clinical Trials, which collects information about ongoing and future drug testing, Novo Nordisk is also preparing for a phase III trial comparing Mim8, which is based on Genmab’s Duobody technology platform, to other medicines in children with hemophilia A.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app